Search

everythinglearnresearchcommunity

for

Search:↓

Female donor to male recipient sex mismatch and positive ACA-IgG are key risk factors for vitiligo and alopecia areata in chronic GvHD patients.

Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.

Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.

The document tests knowledge and decision-making in hematology through multiple-choice questions.

The document provides 70 multiple choice questions to improve haematology skills.

Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.

Many research paper titles in dermatology journals lack scientific precision.

The model and estimator can predict drug exposure in kidney transplant patients well.

The study found that severe alopecia areata affects any age, treatments often give temporary results, and some factors predict worse outcomes.

Both atopy and eosinophilia are linked to more severe hair loss in people with alopecia areata.

Cryotherapy helps reduce chemotherapy side effects but needs more research for best use.

JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.

TLR4 is important in aging-related diseases and could be a new treatment target.

The conclusion is that more hair loss (androgenetic alopecia) is linked to larger prostate size, suggesting hair loss could be an early sign of benign prostatic hyperplasia.

Genomic profiling for myeloid cancers can find important inherited mutations, but it's challenging when these mutations aren't related to the patient's symptoms.

Some children who had stem cell transplants developed permanent hair loss, especially when treated with a drug called busulphan.

The document concludes that treatment for cutaneous T-cell lymphoma should be customized to each patient's disease stage, balancing benefits and side effects, with no cure but many patients living long lives.

Permanent hair loss after a stem cell transplant can be a sign of chronic immune system attack on the scalp.

Patients with GATA2 deficiency show early skin symptoms that help diagnose the condition.

A woman's sudden hair loss three years after a bone marrow transplant was a sign of chronic graft-versus-host disease but improved with treatment.

Folliculotropic mycosis fungoides has a worse prognosis than other types, with survival rates varying significantly based on subtype and organ involvement.

Skin changes like hair loss, white patches, and nail changes are common in children after bone marrow transplants, often linked to chronic rejection.

The document concludes that low-dose oral minoxidil successfully regrew hair in a patient with permanent hair loss after chemotherapy and stem cell transplant.

The secretome from mesenchymal stem cells is a promising treatment that may repair tissue and avoid side effects of stem cell transplantation.

The secretions of mesenchymal stem cells could be used for healing without using the cells themselves.

Stem-cell therapy shows promise for skin conditions but needs more research.

Cell therapy shows promise for treating severe psoriasis but needs more research to confirm safety and effectiveness.

Mice with human fetal thymic tissue and stem cells developed symptoms similar to chronic graft-versus-host disease.

Newborn screening and gene therapy are expected to improve outcomes for Omenn syndrome patients.

Standard treatment for congenital erythropoietic porphyria was ineffective over five years.